Clinical trials: Conjunctiva; Disorder
Bacterial Conjunctivitis
Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003)
The purpose of this study is to evaluate the clinical and microbial efficacy and safety of AzaSite compared to vehicle for bacterial conjunctivitis.
- Trial name
- NCT00105534
- Testing
- AzaSite, Vehicle
- Where
- 32 sites in United States
- Volunteers
- 685 people
- Sponsor
- Merck Sharp & Dohme LLC
Bacterial Conjunctivitis
A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis
This is a 7 day study to evaluate the safety and efficacy of topical gatifloxacin ophthalmic solution for the treatment of bacterial conjunctivitis in subjects from birth to 31 days of age
- Trial name
- NCT00464438
- Testing
- gatifloxacin, moxifloxacin 0.5% eye drops
- Where
- 2 sites in United States, Canada
- Volunteers
- 171 people
- Sponsor
- Allergan
Allergic Conjunctivitis, Seasonal Allergies
A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis
This is a randomized, parallel, single center, double masked, vehicle controlled study. The purpose of this study is to determine the activity and safety of NS2 in patients with grass, tree or ragweed-pollen induced seasonal…
- Trial name
- NCT02578914
- Testing
- NS2 Ophthalmic Drops (0.5%), NS2 Ophthalmic Drops Vehicle (0.0%)
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Allergic Conjunctivitis
Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects
The purpose of this study is to evaluate olopatadine 0.2% QD (once per day) compared to olopatadine 0.1% BID (twice per day) in the treatment of ocular itching associated with allergic conjunctivitis.
- Trial name
- NCT02322216
- Testing
- Olopatadine Hydrochloride Ophthalmic Solution 0.2%, Olopatadine Hydrochloride Ophthalmic Solution 0.1%, Olopatadine 0.2% Vehicle
- Volunteers
- 383 people
- Sponsor
- Alcon Research
Allergic Conjunctivitis
Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan
The purpose of this study is to evaluate the effectiveness and safety of Olopatadine Hydrochloride (HCl) ophthalmic solution 0.1% versus Epinastine HCl ophthalmic solution, 0.05% in a population of healthy, adult Japanese…
- Trial name
- NCT02251613
- Testing
- Olopatadine HCl ophthalmic solution, 0.1%, Epinastine HCl ophthalmic solution, 0.05%
- Volunteers
- 50 people
- Sponsor
- Alcon Research
Keratoconjunctivitis Sicca
Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease
This study will evaluate the efficacy of cyclosporine ophthalmic solution vs. other non-prescription treatments in patients with dry eye disease.
- Trial name
- NCT00717418
- Testing
- cyclosporine ophthalmic emulsion 0.05%, artificial tears
- Where
- United States
- Volunteers
- 781 people
- Sponsor
- Allergan
Pterygium
RMP-A03 Ocular Suspension in Patients With Pterygium
The goal of this clinical trial is to test the safety and efficacy of an ocular medication on the treatment of pterygium.
- Trial name
- NCT05794204
- Testing
- RMP-A03 - Dose 1, RMP-A03 - Dose 2
- Where
- 6 sites in United States
- Volunteers
- 77 people
- Sponsor
- Suzhou Raymon Pharmaceuticals Company, Ltd.
Conjunctivitis, Allergic
A Study of ADX-102 in Subjects With Allergic Conjunctivitis
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Phase 2b Evaluation of the Onset and Duration of ADX-102 Ophthalmic Drops (0.5% and 0.1%) Compared to Vehicle of ADX-102 Ophthalmic Drops in the Conjunctival Allergen…
- Trial name
- NCT03012165
- Testing
- ADX-102 Ophthalmic Drops (0.5%), ADX-102 Ophthalmic Drops (0.1%), Vehicle of ADX-102 Ophthalmic Drops
- Where
- 5 sites in United States
- Volunteers
- 154 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Atopic Conjunctivitis
Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis
This study evaluates the efficacy and safety of Cyclosporine 0.010% eye drops in the treatment of Atopic Keratoconjunctivitis (chronic and severe inflammation of the eye).
- Trial name
- NCT00884585
- Testing
- Cyclosporine Vehicle, Cyclosporine 0.010%
- Where
- 12 sites in United States, Australia and 10 more
- Volunteers
- 176 people
- Sponsor
- Allergan
Trachoma
Safety and Immunogenicity of a Chlamydia Vaccine CTH522
CHLM-02 was a phase I, double-blind, randomized, placebo-controlled trial of the chlamydia vaccine CTH522. 65 trial participants were randomized into 12 groups and six cohorts (A1 to F2).
- Trial name
- CHLM-02 (NCT03926728)
- Testing
- CTH522-CAF01 IM, CTH522-CAF09b IM, CTH522 ID
- Where
- United Kingdom
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Statens Serum Institut
Allergic Conjunctivitis
A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle
A Single-Center study to demonstrate the non-inferiority of EM-100 to Zaditor® in the treatment of ocular itching.
- Trial name
- NCT03489941
- Testing
- EM-100, Zaditor®, Vehicle
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Bausch & Lomb Incorporated
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease.
- Trial name
- STRIDE 1 (NCT02813265)
- Testing
- KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension
- Where
- 60 sites in United States
- Volunteers
- 918 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Keratoconjunctivitis Sicca
An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
This is a safety extension enrolling subjects participating in Study OTX-101-2016-001 (NCT02688556)
- Trial name
- NCT02845674
- Testing
- OTX-101 0.09%
- Volunteers
- 258 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Conjunctivitis, Allergic
AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis
This study will evaluate the safety and efficacy of AGN-229666 for the treatment of seasonal or perennial allergic conjunctivitis.
- Trial name
- NCT02082262
- Testing
- AGN-229666
- Where
- Japan
- Volunteers
- 140 people
- Sponsor
- Allergan
Chlamydial Conjunctivitis
The Effect of Oral Azithromycin in the Treatment of Chlamydial Conjunctivitis
Chlamydia trachomatis is one of the major causes of sexually transmitted disease and also the leading infectious cause of blindness in the world.Treatment of C. trachomatis eye infection has involved for a long time.
- Trial name
- NCT01178762
- Testing
- Azithromycin
- Where
- Taiwan
- Volunteers
- 42 people
- Sponsor
- National Taiwan University Hospital
Eye Dryness
Comparison of Two Marketed Lenses in a Controlled Environment
This study is comparing two silicone hydrogel contact lenses in a controlled environment for identification of characteristics associated to vision.
- Trial name
- NCT02212301
- Testing
- senofilcon A, lotrafilcon B
- Where
- United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Vision Care, Inc.
Allergic Conjunctivitis
A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy
A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft ® as Measured by In-Vivo Confocal Microscopy
- Trial name
- NCT02308501
- Testing
- Lastacaft ®
- Volunteers
- 25 people
- Sponsor
- ORA, Inc.
Conjunctivitis, Allergic
AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis
This study will evaluate the safety and efficacy of AGN-229666 for the prevention of allergen-mediated conjunctivitis.
- Trial name
- NCT02161146
- Testing
- AGN-229666, Vehicle to AGN-229666, Olopatadine
- Where
- Japan
- Volunteers
- 240 people
- Sponsor
- Allergan
Bacterial Conjunctivitis
Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis
The objective of this study is to evaluate the safety and efficacy of Besivance (besifloxacin 0.6%) ophthalmic suspension compared to gatifloxacin 0.3% ophthalmic solution when administered three times daily (TID) for seven days…
- Trial name
- NCT01330355
- Testing
- Besivance, Gatifloxacin
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Bausch & Lomb Incorporated
Allergic Conjunctivitis
A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model
To evaluate the efficacy of Bilastine Ophthalmic Solution (0.2%,0.4%,0.6%) compared to vehicle for the treatment of the signs and symptoms of allergic conjunctivitis
- Trial name
- NCT03231969
- Testing
- Bilastine 0.2%, Bilastine 0.4%, Bilastine 0.6%
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Faes Farma, S.A.